Breaking News Instant updates and real-time market news.

2020-12-02 16:40:38 LLY Eli Lilly $145.17 / -0.35 (-0.24%) 16:40 12/02/20 12/02 16:40 12/02/20 16:40	Eli Lilly says updated purchase of LY-CoV555 to boost FY20 EPS view by 25c The company states: "In 2020, the estimated impact of the updated purchase agreement to the guidance range provided in Lilly's earnings release on October 27, 2020 is approximately $500 million of additional revenue and approximately 25 cents of additional earnings per share." TheFly notes that on October 27th, Eli Lilly affirmed its FY20 EPS view of $7.20-$7.40 and revenue view of $23.7B-$24.2B. The impact from the updated order brings that guidance to $7.45-$7.65 vs. consensus $7.25 and revenue of $24.2B-$24.7B vs. consensus $23.72B.	05 Dec 08 Dec 15 Dec 29 Jan
LLY Eli Lilly $145.17 / -0.35 (-0.24%) 11/20/20 Stifel Precision BioSciences price target raised to $22 from $21 at Stifel 11/17/20 Mizuho Eli Lilly price target lowered to $156 from $164 at Mizuho 11/10/20 Bernstein Eli Lilly initiated with a Market Perform, $150 price target at Bernstein 11/10/20 Bernstein Eli Lilly initiated with a Market Perform at Bernstein

2020-12-02 16:40:38

LLY

Eli Lilly

$145.17 / -0.35 (-0.24%)

16:40

12/02/20

12/02

16:40

12/02/20

16:40

Eli Lilly says updated purchase of LY-CoV555 to boost FY20 EPS view by 25c

The company states: "In 2020, the estimated impact of the updated purchase agreement to the guidance range provided in Lilly's earnings release on October 27, 2020 is approximately $500 million of additional revenue and approximately 25 cents of additional earnings per share." TheFly notes that on October 27th, Eli Lilly affirmed its FY20 EPS view of $7.20-$7.40 and revenue view of $23.7B-$24.2B. The impact from the updated order brings that guidance to $7.45-$7.65 vs. consensus $7.25 and revenue of $24.2B-$24.7B vs. consensus $23.72B.

05
Dec
08
Dec
15
Dec
29
Jan

LLY Eli Lilly

$145.17 / -0.35 (-0.24%)

11/20/20 Stifel: Precision BioSciences price target raised to $22 from $21 at Stifel

11/17/20 Mizuho: Eli Lilly price target lowered to $156 from $164 at Mizuho

11/10/20 Bernstein: Eli Lilly initiated with a Market Perform, $150 price target at Bernstein

11/10/20 Bernstein: Eli Lilly initiated with a Market Perform at Bernstein

TODAY'S FREE FLY STORIES

Upgrade	Royal Mail upgraded to Buy from Hold at Deutsche Bank » 05:57 01/20/21 01/20 05:57 01/20/21 05:57 ROYMY Royal Mail $0.00 / + (+0.00%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research ROYMY Royal Mail $0.00 / + (+0.00%) 01/08/21 Barclays Royal Mail price target raised to 350 GBp from 300 GBp at Barclays 01/05/21 Berenberg Royal Mail upgraded to Hold from Sell at Berenberg 12/01/20 Liberum Royal Mail upgraded to Hold from Sell at Liberum 11/24/20 UBS Royal Mail downgraded to Neutral from Buy at UBS
Initiation	Repay Holdings initiated with an Equal Weight at Wells Fargo » 05:56 01/20/21 01/20 05:56 01/20/21 05:56 RPAY Repay Holdings $25.11 / +0.94 (+3.89%) Wells Fargo analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate RPAY Repay Holdings $25.11 / +0.94 (+3.89%) 12/07/20 Repay Holdings announces partnership with SHRO 10/27/20 Repay Holdings to acquire CPS Payment Services for up to $93M 10/07/20 Repay announces integration with Ellie Mae 07/23/20 Repay Holdings acquires cPayPlus for up to $16M RPAY Repay Holdings $25.11 / +0.94 (+3.89%) 10/05/20 Morgan Stanley Repay Holdings initiated with an Equal Weight at Morgan Stanley 09/17/20 Barclays Repay Holdings initiated with an Overweight at Barclays 08/11/20 Canaccord Repay Holdings price target raised to $30 from $26 at Canaccord 06/17/20 DA Davidson Repay Holdings price target raised to $31 from $20 at DA Davidson RPAY Repay Holdings $25.11 / +0.94 (+3.89%) 11/09/20 Repay Holdings reports Q3 adjusted EPS 12c 14 Jan 10 Sep 29 May
Conference/Events	H&R Block management to meet virtually with Oppenheimer » 05:55 01/20/21 01/20 05:55 01/20/21 05:55 HRB H&R Block $16.42 / -0.07 (-0.42%) Virtual Meetings to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options HRB H&R Block $16.42 / -0.07 (-0.42%) 12/08/20 H&R Block to present next phase of strategic transformation 10/19/20 Truist Financial names Vinoo Vijay as Chief Marketing Officer 10/06/20 H&R Block appoints Yolande Piazza to board of directors 09/04/20 Etsy, Teradyne, Catalent to join S&P 500 HRB H&R Block $16.42 / -0.07 (-0.42%) 10/30/20 BTIG BTIG thinks those looking to potentially short Square, H&R Block should wait 09/03/20 BMO Capital H&R Block price target lowered to $17 from $19 at BMO Capital 09/01/20 BTIG H&R Block's tax season distorted by pandemic, say BTIG 07/15/20 Northcoast H&R Block upgraded to Buy from Neutral at Northcoast HRB H&R Block $16.42 / -0.07 (-0.42%) 12/08/20 H&R Block reports Q2 adj. EPS ($1.09), consensus (94c) 12/07/20 Notable companies reporting before tomorrow's open 12/07/20 Notable companies reporting before tomorrow's open 09/01/20 H&R Block reports Q1 adj. EPS 55c, consensus 50c HRB H&R Block $16.42 / -0.07 (-0.42%) 12/08/20 Fly Intel: Pre-market Movers 11/19/20 Rising High: An exclusive talk with multi-state operator Orchid Ventures 09/08/20 Tesla slides after being snubbed by S&P 500 Index 09/02/20 Fly Intel: Pre-market Movers 00:00 Today H&R Block HRB H&R Block $16.42 / -0.07 (-0.42%) 09/01/20 H&R Block options imply 11.3% move in share price post-earnings
Conference/Events	Genetron management to meet virtually with BTIG » 05:55 01/20/21 01/20 05:55 01/20/21 05:55 GTH Genetron $23.34 / +3.13 (+15.49%) Virtual Meetings to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events GTH Genetron $23.34 / +3.13 (+15.49%) 01/06/21 Genetron, CTTQ enter exclusive partnership agreement for HCCscreen 11/27/20 Genetron says HCCscreen selected by NCC, Wuxi for public health initiative 10/22/20 Genetron signs licensing agreement with ImmuQuad Bio for residual cancer assays 09/30/20 Genetron receives Breakthrough Device designation for NGS test HCCscreen GTH Genetron $23.34 / +3.13 (+15.49%) 09/30/20 Canaccord Genetron China opportunity understated with current valuation, says Canaccord 08/03/20 Canaccord Genetron outlook positive ahead of results, says Canaccord 07/14/20 BTIG Genetron initiated with a Buy at BTIG GTH Genetron $23.34 / +3.13 (+15.49%) 08/06/20 Genetron reports Q2 adjusted EPS (4c), consensus (9c) 19 Jun GTH Genetron $23.34 / +3.13 (+15.49%) 01/06/21 Fly Intel: Wall Street's top stories for Wednesday 01/06/21 Fly Intel: Wall Street's top stories at midday 09/30/20 Fly Intel: Wall Street's top stories for Wednesday 09/30/20 Fly Intel: Wall Street's top stories at midday 00:00 Today Genetron
Downgrade	Boralex downgraded to Sector Perform from Outperform at National Bank » 05:53 01/20/21 01/20 05:53 01/20/21 05:53 BRLXF Boralex $0.00 / + (+0.00%) National Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research BRLXF Boralex $0.00 / + (+0.00%) 01/13/21 CIBC Boralex price target raised to C$55 from C$43 at CIBC 01/06/21 National Bank Boralex price target raised to C$50 from C$43 at National Bank 12/01/20 Credit Suisse Boralex initiated with a Neutral at Credit Suisse 11/25/20 RBC Capital Boralex price target raised to C$42 from C$40 at RBC Capital

Upgrade	Netflix upgraded to Overweight with $700 price target at Wells Fargo » 05:51 01/20/21 01/20 05:51 01/20/21 05:51 NFLX Netflix $501.85 / +3.9 (+0.78%) Wells Fargo analyst… Wells Fargo analyst Steven Cahall upgraded Netflix to Overweight from Equal Weight with a price target of $700, up from $510 following last night's Q4 results. While Q4 net additions of 8.5M beat expectations, the company's operating leverage "really impressed," Cahall tells investors in a research note. Netflix is now "effectively cash sustaining," says the analyst. He believes that with "little to hinder pricing growth," and the subscriber base still expanding, Netflix can afford to "grow cash content spend AND deliver strong operating leverage." He sees the long-term economics "providing a catalyst runway" for Netflix shares. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options NFLX Netflix $501.85 / +3.9 (+0.78%) 01/19/21 Netflix says 'super proud' of free cash flow 01/19/21 Netflix says not necessarily through the 'pull forward' of 2020 01/19/21 Netflix says past year 'testament' to company's approach 01/19/21 Netflix says 'very close to being sustainably FCF positive' NFLX Netflix $501.85 / +3.9 (+0.78%) 05:11 Today Wells Fargo Netflix upgraded to Overweight from Equal Weight at Wells Fargo 05:01 Today Piper Sandler Netflix price target raised to $652 from $643 at Piper Sandler 04:52 Today Pivotal Research Netflix price target raised to $750 from $660 at Pivotal Research 04:41 Today UBS Netflix upgraded to Buy from Neutral at UBS NFLX Netflix $501.85 / +3.9 (+0.78%) 01/19/21 Netflix sees Q1 EPS $2.97, consensus $2.10 01/19/21 Netflix reports Q4 EPS $1.19, consensus $1.39 01/19/21 Notable companies reporting after market close 10/20/20 Netflix sees Q4 EPS $1.35, consensus 94c NFLX Netflix $501.85 / +3.9 (+0.78%) 01/15/21 Data suggests Netflix North American usage dipped in Q4, Business Insider says 01/06/21 Netflix raising prices for some UK subscription plans, BBC reports 12/15/20 Netflix streaming experiences outage for over 1,000 users, Reuters says 12/07/20 Netflix sued by Activision over allegedly poaching former CFO, WSJ reports NFLX Netflix $501.85 / +3.9 (+0.78%) 01/19/21 Fly Intel: After-Hours Movers 01/19/21 Fly Intel: What to watch in Netflix earnings report 01/15/21 Spotify plunges after downgrade, report of Apple podcast ambitions 01/15/21 Accolade upgrade, Spotify downgrade among today's top calls on Wall Street NFLX Netflix $501.85 / +3.9 (+0.78%) 01/19/21 Netflix options imply 9.5% move in share price post-earnings 12/31/20 Early notable gainers among liquid option names on December 31st 10/26/20 Early notable gainers among liquid option names on October 26th 10/21/20 Notable open interest changes for October 21st
Downgrade	Rightmove downgraded to Underperform from Neutral at BofA » 05:47 01/20/21 01/20 05:47 01/20/21 05:47 RTMVY Rightmove $0.00 / + (+0.00%) BofA downgraded Rightmove… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research RTMVY Rightmove $0.00 / + (+0.00%) 01/12/21 Berenberg Rightmove price target raised to 440 GBp from 400 GBp at Berenberg 12/15/20 JPMorgan Rightmove price target lowered to 517 GBp from 542 GBp at JPMorgan 11/27/20 UBS Rightmove price target raised to 620 GBp from 545 GBp at UBS 09/03/20 Barclays Rightmove price target raised to 525 GBp from 450 GBp at Barclays
Upgrade	DSM upgraded to Outperform from Neutral at Credit Suisse » 05:47 01/20/21 01/20 05:47 01/20/21 05:47 RDSMY DSM $0.00 / + (+0.00%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research RDSMY DSM $0.00 / + (+0.00%) 01/12/21 Bernstein DSM downgraded to Underperform from Market Perform at Bernstein 11/19/20 Barclays DSM price target raised to EUR 160 from EUR 153 at Barclays 11/18/20 Barclays DSM price target raised to EUR 160 from EUR 153 at Barclays 11/18/20 Berenberg DSM price target raised to EUR 150 from EUR 135 at Berenberg
Downgrade	ProsiebenSat downgraded to Underperform from Neutral at BofA » 05:47 01/20/21 01/20 05:47 01/20/21 05:47 PBSFY ProsiebenSat $0.00 / + (+0.00%) BofA downgraded… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research PBSFY ProsiebenSat $0.00 / + (+0.00%) 01/12/21 Berenberg ProsiebenSat price target raised to EUR 14.50 from EUR 13.35 at Berenberg 12/08/20 JPMorgan ProsiebenSat price target raised to EUR 19.50 from EUR 18 at JPMorgan 11/10/20 Deutsche Bank ProsiebenSat price target raised to EUR 14 from EUR 12 at Deutsche Bank 11/06/20 Credit Suisse ProsiebenSat price target raised to EUR 6.50 from EUR 5.80 at Credit Suisse
Downgrade	Beyond Meat downgraded to Neutral from Buy at BTIG » 05:43 01/20/21 01/20 05:43 01/20/21 05:43 BYND Beyond Meat $141.70 / +1.56 (+1.11%) BTIG analyst Peter Saleh… BTIG analyst Peter Saleh downgraded Beyond Meat to Neutral from Buy without a price target. The analyst believes growth through the retail channel will not be enough to sustain the company's growth rate and "hefty trading multiple" in 2021. While Saleh continues to believe in the long-term trend toward plant-based meats in the grocery and foodservice channels, he expects restaurant operators will remain focused on throughput over menu innovation, limiting adoption and sales growth through the foodservice channel this year. Further, recent international lockdowns, primarily across Europe, will continue to weigh on new partnerships and sales growth for Beyond Meat until a vaccine is widely available and dining rooms reopen, says the analyst. Shah cites a weaker sales growth outlook, heightened price competition and "elevated valuation" for the downgrade of the shares. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options BYND Beyond Meat $141.70 / +1.56 (+1.11%) 01/15/21 Beyond Meat announces plans for new global headquarters 01/14/21 Taco Bell exploring new plant-based protein with Beyond Meat 11/16/20 Beyond Meat unveils next iteration of Beyond Burger for early 2021 11/10/20 Beyond Meat CEO: Really excited about launch with Pizza Hut BYND Beyond Meat $141.70 / +1.56 (+1.11%) 01/19/21 JPMorgan JPMorgan sees 33% downside in Beyond Meat shares, cuts target to $94 01/06/21 Fly Intel: Top five analyst downgrades 01/06/21 Piper Sandler Beyond Meat downgraded on lagging momentum, estimate risk at Piper Sandler 01/05/21 Piper Sandler Beyond Meat downgraded to Neutral from Overweight at Piper Sandler BYND Beyond Meat $141.70 / +1.56 (+1.11%) 11/09/20 Beyond Meat reports Q3 adj. EPS (28c), consensus 5c 11/09/20 Notable companies reporting after market close 08/04/20 Beyond Meat 2020 outlook remains suspended 08/04/20 Beyond Meat reports Q2 EPS (2c), consensus (4c) BYND Beyond Meat $141.70 / +1.56 (+1.11%) 11/09/20 Beyond Meat up 4% after confirming partnership with McDonald's for 'McPlant' 11/09/20 Beyond Meat says co-created 'McPlant' burger with McDonald's, Reuters reports 09/29/20 Chanos says Beyond Meat expansion at Walmart previously announced 09/22/20 Impossible Foods enters Canadian fast casual market, Techcrunch reports BYND Beyond Meat $141.70 / +1.56 (+1.11%) 01/06/21 Coca-Cola, PepsiCo downgrades among today's top calls on Wall Street 11/10/20 Fly Intel: Wall Street's top stories for Tuesday 11/10/20 Fly Intel: Wall Street's top stories at midday 11/10/20 Beyond Meat plunges following surprise loss on 'full brunt of COVID' BYND Beyond Meat $141.70 / +1.56 (+1.11%) 01/13/21 Largest borrow rate increases among liquid names 11/18/20 Unusually active option classes on open November 18th 10/06/20 Beyond Meat call volume above normal and directionally bullish 09/29/20 Beyond Meat call volume above normal and directionally bullish

Recommendations	General Motors added to US 1 List at BofA 05:42 01/20/21 01/20 05:42 01/20/21 05:42 GM General Motors $54.85 / +4.88 (+9.77%) ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options GM General Motors $54.85 / +4.88 (+9.77%) 01/19/21 EU passenger car registrations down 3.3% in December 01/19/21 General Motors jumps 6% to $53.25 after Microsoft invests in Cruise 01/19/21 General Motors, Cruise announce long-term relationship with Microsoft 01/12/21 General Motors announces launch of new BrightDrop business unit GM General Motors $54.85 / +4.88 (+9.77%) 01/14/21 Fly Intel: Top five analyst upgrades 01/14/21 Argus General Motors upgraded to Buy at Argus on business expansion, high margins 01/14/21 Argus General Motors upgraded to Buy from Hold at Argus 01/13/21 Fly Intel: Top five analyst upgrades GM General Motors $54.85 / +4.88 (+9.77%) 11/05/20 General Motors reports Q3 adjusted EPS $2.83, consensus $1.38 11/04/20 Notable companies reporting before tomorrow's open 11/04/20 Notable companies reporting before tomorrow's open 10/13/20 Fly Intel: What to watch in next round of big banks' earnings reports GM General Motors $54.85 / +4.88 (+9.77%) 01/17/21 GM to invest $800M for EV output at Ontario plant, Bloomberg reports 01/14/21 GM planning expansion of Corvette line into SUVs, Bloomberg reports 01/14/21 General Motors planning expansion of Corvette line into SUVs, Bloomberg says 01/12/21 GM introduces new logistics-focused EV business unit at CES, CNET reports GM General Motors $54.85 / +4.88 (+9.77%) 01/19/21 Fly Intel: Wall Street's top stories for Tuesday 01/19/21 Fly Intel: Wall Street's top stories at midday 01/14/21 Shopify, Intel upgrades among today's top calls on Wall Street 01/13/21 Tesla initiation, Home Depot upgrade among today's top calls on Wall Street GM General Motors $54.85 / +4.88 (+9.77%) 01/19/21 Early notable gainers among liquid option names on January 19th 01/13/21 Early notable gainers among liquid option names on January 13th 01/13/21 Unusual call flow in option market yesterday 01/12/21 Call buyer hits the gas in General Motors
Upgrade	Polaris upgraded to Outperform from Market Perform at BMO Capital » 05:39 01/20/21 01/20 05:39 01/20/21 05:39 PII Polaris $113.25 / +5.25 (+4.86%) BMO Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PII Polaris $113.25 / +5.25 (+4.86%) 12/22/20 Polaris appoints Michael Speetzen interim CEO 11/18/20 Polaris falls -6.6% 11/17/20 Polaris CEO Scott Wine to leave to assume CEO role at CNH Industrial 11/17/20 CNH Industrial names Scott W. Wine CEO PII Polaris $113.25 / +5.25 (+4.86%) 01/19/21 Morgan Stanley Polaris initiated with an Overweight at Morgan Stanley 01/19/21 Wedbush Polaris price target raised to $126 from $116 at Wedbush 01/05/21 Baird Polaris added to 2021 Best Idea list at Baird 11/27/20 Citi adds Polaris to 'Value Creators' SMID Focus List, removes Knight-Swift PII Polaris $113.25 / +5.25 (+4.86%) 11/17/20 Polaris backs FY20 adjusted EPS view $7.15-$7.30, consensus $7.28 10/27/20 Polaris sees Q4 revenue growing sequentially, consensus $1.95B 10/27/20 Polaris raises FY20 adj. EPS view to $7.15-$7.30 from $6.40-$6.60 10/27/20 Polaris reports Q3 EPS $2.66, consensus $2.19 PII Polaris $113.25 / +5.25 (+4.86%) 11/17/20 Fly Intel: After-Hours Movers 07/28/20 Fly Intel: Pre-market Movers 01/26/21 Polaris - PII
Downgrade	Standard Chartered downgraded to Neutral from Buy at Citi » 05:37 01/20/21 01/20 05:37 01/20/21 05:37 SCBFF Standard Chartered $0.00 / + (+0.00%) Citi analyst Ronit Ghose… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals SCBFF Standard Chartered $0.00 / + (+0.00%) 08/11/20 Standard Chartered, Microsoft announce three-year strategic partnership SCBFF Standard Chartered $0.00 / + (+0.00%) 01/11/21 Deutsche Bank Standard Chartered price target raised to 560 GBp from 480 GBp at Deutsche Bank 01/07/21 Investec Standard Chartered downgraded to Hold from Buy at Investec 11/25/20 Barclays Standard Chartered price target raised to 410 GBp from 400 GBp at Barclays 10/20/20 Deutsche Bank Deutsche Bank opens 'Sell Catalyst Call' on Standard Chartered SCBFF Standard Chartered $0.00 / + (+0.00%) 01/15/21 Standard Chartered planning additional job cuts, Bloomberg says 10/07/20 Standard Chartered to eliminate over 100 UAE positions, Bloomberg reports 09/21/20 JPMorgan, other banks moved large sums of illicit cash, ICIJ reports
Downgrade	Michaels downgraded to Underweight from Equal Weight at Morgan Stanley » 05:35 01/20/21 01/20 05:35 01/20/21 05:35 MIK Michaels $16.37 / -0.12 (-0.73%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options MIK Michaels $16.37 / -0.12 (-0.73%) 12/03/20 Michaels to pay $10M in one-time holiday bonuses to employees in Q4 09/25/20 Michaels expects top-line growth of 1.5%-2.5% over next 5 years 09/23/20 Bed Bath & Beyond names Scott Lindblom as Chief Technology Officer 09/08/20 Michaels to hire over 16,000 holiday employees MIK Michaels $16.37 / -0.12 (-0.73%) 12/14/20 JPMorgan Michaels downgraded to Neutral after recent rally at JPMorgan 12/14/20 JPMorgan Michaels downgraded to Neutral from Overweight at JPMorgan 12/04/20 Fly Intel: Top five analyst upgrades 12/04/20 Morgan Stanley Morgan Stanley upgrades 'healthier' Michaels to Equal Weight MIK Michaels $16.37 / -0.12 (-0.73%) 12/03/20 Michaels sees Q4 sales up in the mid-single digits, consensus $1.82B 12/03/20 Michaels reports Q3 adj. EPS 86c, consensus 59c 12/02/20 Notable companies reporting before tomorrow's open 12/02/20 Notable companies reporting before tomorrow's open MIK Michaels $16.37 / -0.12 (-0.73%) 12/03/20 Fly Intel: Pre-market Movers 10/12/20 Fly Insider: Element Solutions, Sunrun among week's notable insider trades 09/04/20 Lululemon, Wayfair downgrades among today's top calls on Wall Street 09/03/20 Fly Intel: Pre-market Movers MIK Michaels $16.37 / -0.12 (-0.73%) 08/20/20 Michaels call volume above normal and directionally bullish 07/29/20 Largest borrow rate increases among liquid names
Upgrade	NuStar Energy upgraded to Neutral from Underweight at JPMorgan » 05:34 01/20/21 01/20 05:34 01/20/21 05:34 NS NuStar Energy $15.90 / -0.03 (-0.19%) JPMorgan analyst Joseph… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events NS NuStar Energy $15.90 / -0.03 (-0.19%) 11/05/20 NuStar Energy raises 2020 adjusted EBITDA view to $690M-$730M 11/02/20 NuStar Energy to sell Texas City terminals to BWC Terminals for $106M 10/05/20 NuStar subsidiary issued permit to operate existing pipeline Border facilities 08/04/20 NuStar Energy reaffirms FY20 adjusted EBITDA view $665M-$735M NS NuStar Energy $15.90 / -0.03 (-0.19%) 01/15/21 Barclays NuStar Energy reinstated with an Overweight at Barclays 01/06/21 BofA NuStar Energy downgraded to Underperform from Neutral at BofA 01/06/21 BofA NuStar Energy downgraded to Underperform from Neutral at BofA 12/03/20 SMBC Nikko NuStar Energy initiated with a Neutral at SMBC Nikko NS NuStar Energy $15.90 / -0.03 (-0.19%) 11/05/20 NuStar Energy reports Q3 adjusted EPS 8c, consensus (9c) 08/04/20 NuStar Energy reports Q2 EPS (6c), consensus 13c 02/04/21 NuStar Energy - NS

Downgrade	Kroger downgraded to Underweight from Equal Weight at Morgan Stanley » 05:34 01/20/21 01/20 05:34 01/20/21 05:34 KR Kroger $33.62 / -0.08 (-0.24%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options KR Kroger $33.62 / -0.08 (-0.24%) 01/08/21 Ralphs provides first doses of COVID vaccine to health care workers in SoCal 12/22/20 Kroger Health to provide Covid-19 vaccine nationwide 12/03/20 Kroger drops 4% to $30.90 after Q3 results, FY20 guidance 12/03/20 Kroger CFO sees strong FY21 performance KR Kroger $33.62 / -0.08 (-0.24%) 01/12/21 BMO Capital Albertsons downgraded to Market Perform from Outperform at BMO Capital 01/07/21 Barclays Kroger downgraded to Underweight from Equal Weight at Barclays 12/04/20 Fly Intel: Top five analyst downgrades 12/04/20 R5 Capital Kroger downgraded to Hold after earnings at R5 Capital KR Kroger $33.62 / -0.08 (-0.24%) 12/03/20 Kroger raises FY20 adjusted EPS view to $3.30-$3.35 from $3.20-$3.30 12/03/20 Kroger reports Q3 adjusted EPS 71c, consensus 67c 12/02/20 Notable companies reporting before tomorrow's open 12/02/20 Notable companies reporting before tomorrow's open KR Kroger $33.62 / -0.08 (-0.24%) 09/14/20 Kroger CEO says grocery demand to stay strong after pandemic, Bloomberg says 08/11/20 Walmart, Instacart partner for same-day delivery in the U.S., CNBC reports KR Kroger $33.62 / -0.08 (-0.24%) 12/03/20 Fly Intel: Wall Street's top stories for Thursday 12/03/20 Fly Intel: Pre-market Movers 11/09/20 Fly Intel: What to watch in Beyond Meat earnings report 10/14/20 Microsoft resumption, Nio upgrade among top calls on Wall Street KR Kroger $33.62 / -0.08 (-0.24%) 12/11/20 Kroger call volume above normal and directionally bullish 12/03/20 Unusually active option classes on open December 3rd 11/23/20 Kroger call volume above normal and directionally bullish 11/11/20 Kroger put volume heavy and directionally bearish
Downgrade	Xenia Hotels downgraded to Underweight from Equal Weight at Morgan Stanley » 05:33 01/20/21 01/20 05:33 01/20/21 05:33 XHR Xenia Hotels $16.64 / +0.245 (+1.49%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events XHR Xenia Hotels $16.64 / +0.245 (+1.49%) 10/14/20 Xenia Hotels estimates average monthly recurring cash expenses of $16.5M 10/14/20 Xenia Hotels says 37 of the company's 38 hotels, resorts are open, operating 08/27/20 Xenia Hotels provides update on credit facilities, $100M sale of Marriott hotel XHR Xenia Hotels $16.64 / +0.245 (+1.49%) 01/12/21 Fly Intel: Top five analyst upgrades 01/12/21 Raymond James Xenia Hotels upgraded to Outperform on leisure exposure at Raymond James 01/12/21 Raymond James Xenia Hotels upgraded to Outperform from Market Perform at Raymond James 12/14/20 KeyBanc Xenia Hotels downgraded to Sector Weight from Overweight at KeyBanc XHR Xenia Hotels $16.64 / +0.245 (+1.49%) 10/30/20 Xenia Hotels reports Q3 AFFO (27c), consensus (31c) 07/30/20 Xenia Hotels reports Q2 AFFO (46c), consensus (77c) 03/01/21 Xenia Hotels - XHR
Upgrade	Coloplast upgraded to Hold from Sell at Berenberg » 05:33 01/20/21 01/20 05:33 01/20/21 05:33 CLPBY Coloplast $0.00 / + (+0.00%) Berenberg analyst Scott… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Events CLPBY Coloplast $0.00 / + (+0.00%) 01/13/21 Barclays Coloplast price target lowered to DKK 875 from DKK 895 at Barclays 12/09/20 Morgan Stanley Coloplast price target raised to DKK 843 from DKK 788 at Morgan Stanley 11/06/20 Morgan Stanley Coloplast price target lowered to DKK 788 from DKK 822 at Morgan Stanley 11/04/20 JPMorgan Coloplast price target lowered to DKK 880 from DKK 886 at JPMorgan 03/02/21 2021 London Global Healthcare Virtual Conference
Downgrade	Albertsons downgraded to Underweight from Equal Weight at Morgan Stanley » 05:32 01/20/21 01/20 05:32 01/20/21 05:32 ACI Albertsons $17.74 / +0.475 (+2.75%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options ACI Albertsons $17.74 / +0.475 (+2.75%) 11/30/20 Albertsons associates ratify agreement with UFCW local unions 11/24/20 Albertsons implements contactless temperature, health screening 11/19/20 Albertsons incorporates SNAP EBT payments at Drive Up & Go locations 11/12/20 Albertsons to partner with HHS to provide COVID-19 vaccine ACI Albertsons $17.74 / +0.475 (+2.75%) 01/15/21 Tigress Financial Tigress continues to recommend Albertsons purchases, sees further upside 01/15/21 Northcoast Albertsons price target raised to $21 after Q3 report at Northcoast 01/12/21 BMO Capital Albertsons downgraded to Market Perform from Outperform at BMO Capital 01/07/21 Barclays Albertsons downgraded to Underweight from Equal Weight at Barclays ACI Albertsons $17.74 / +0.475 (+2.75%) 01/12/21 Albertsons raises FY20 adjusted EPS view to $3.05-$3.15 from $2.75-$2.85 01/12/21 Albertsons reports Q3 adjusted EPS 66c, consensus 42c 01/11/21 Notable companies reporting before tomorrow's open 01/11/21 Notable companies reporting before tomorrow's open 26 Jun ACI Albertsons $17.74 / +0.475 (+2.75%) 09/19/20 Albertsons a Buy as stock looks cheap, Barron's says ACI Albertsons $17.74 / +0.475 (+2.75%) 01/12/21 Fly Intel: Pre-market Movers 11/09/20 Fly Intel: What to watch in Beyond Meat earnings report 10/20/20 Fly Intel: Pre-market Movers 10/14/20 Fly Intel: After-Hours Movers ACI Albertsons $17.74 / +0.475 (+2.75%) 01/13/21 Largest borrow rate increases among liquid names 01/12/21 Largest borrow rate increases among liquid names 01/11/21 Largest borrow rate increases among liquid names 01/07/21 Largest borrow rate increases among liquid names
Hot Stocks	Kiromic BioPharma announces completion, certification of Houston facility » 05:32 01/20/21 01/20 05:32 01/20/21 05:32 KRBP Kiromic BioPharma $8.70 / +0.31 (+3.69%) Kiromic BioPharma… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Syndicate On The Fly Events KRBP Kiromic BioPharma $8.70 / +0.31 (+3.69%) 12/17/20 Kiromic BioPharma submits to IND applications for CAR-T cell therapy with FDA 16 Oct KRBP Kiromic BioPharma $8.70 / +0.31 (+3.69%) 10/18/20 Opening Day: Array jumps after $1.05B IPO 01/19/21 17th Annual Small & Microcap Virtual Investor Conference

Downgrade	Gritstone Oncology downgraded to Underperform from Outperform at Baird » 05:31 01/20/21 01/20 05:31 01/20/21 05:31 GRTS Gritstone Oncology $22.47 / +16.07 (+251.09%) Baird analyst Madhu Kumar… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings GRTS Gritstone Oncology $22.47 / +16.07 (+251.09%) 01/19/21 Gritstone Oncology signs agreement with NIAID to begin testing COVID-19 vaccine 01/04/21 EcoR1 Capital reports 9.99% passive stake in Gritstone Oncology 12/28/20 Gritstone Oncology announces private placement financings totaling $125M 12/23/20 Gritstone Oncology announces $110M private placement GRTS Gritstone Oncology $22.47 / +16.07 (+251.09%) 07/14/20 BTIG Gritstone Oncology price target lowered to $17 from $31 at BTIG GRTS Gritstone Oncology $22.47 / +16.07 (+251.09%) 11/05/20 Gritstone Oncology reports Q3 EPS (69c), consensus (64c) 08/05/20 Gritstone Oncology reports Q2 EPS (69c), consensus (73c)
Upgrade	Signature Aviation upgraded to Hold from Sell at Berenberg » 05:30 01/20/21 01/20 05:30 01/20/21 05:30 BBAVY Signature Aviation $0.00 / + (+0.00%) Berenberg analyst Eoghan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research BBAVY Signature Aviation $0.00 / + (+0.00%) 11/12/20 Berenberg Signature Aviation price target raised to 205 GBp from 165 GBp at Berenberg 09/09/20 JPMorgan Signature Aviation price target lowered to 245 GBp from 267 GBp at JPMorgan 09/09/20 Barclays Signature Aviation price target raised to 265 GBp from 250 GBp at Barclays 08/26/20 JPMorgan Signature Aviation downgraded to Neutral from Overweight at JPMorgan
Downgrade	Ambu downgraded to Hold from Buy at DNB Markets » 05:30 01/20/21 01/20 05:30 01/20/21 05:30 AMBBY Ambu $0.00 / + (+0.00%) DNB Markets analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research AMBBY Ambu $0.00 / + (+0.00%) 11/12/20 JPMorgan Ambu price target lowered to DKK 184 from DKK 192 at JPMorgan 10/15/20 JPMorgan Ambu price target raised to DKK 192 from DKK 190 at JPMorgan 10/12/20 JPMorgan JPMorgan backs Neutral on Ambu after chairman resignation 08/28/20 JPMorgan Ambu price target lowered to DKK 190 from DKK 219 at JPMorgan
Downgrade	GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse » 05:29 01/20/21 01/20 05:29 01/20/21 05:29 GSK GlaxoSmithKline $38.53 / +0.07 (+0.18%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GSK GlaxoSmithKline $38.53 / +0.07 (+0.18%) 01/12/21 Vir Biotechnology, GlaxoSmithKline to evaluate VIR-7832 in COVID-19 patients 01/11/21 Eligo Bioscience enters research, option agreement with GlaxoSmithKline 12/21/20 Ligand, GSK in pact 'leveraging' Icagen's small molecule 'expertise' 12/17/20 Hikma Pharmaceuticals launches generic Advair Diskus following FDA approval GSK GlaxoSmithKline $38.53 / +0.07 (+0.18%) 01/15/21 Deutsche Bank GlaxoSmithKline initiated with a Hold at Deutsche Bank 12/18/20 H.C. Wainwright Surface Oncology price target raised to $15 from $11 at H.C. Wainwright 12/08/20 JPMorgan GlaxoSmithKline price target lowered to 1,500 GBp from 1,650 GBp at JPMorgan 12/03/20 Fly Intel: Top five analyst downgrades GSK GlaxoSmithKline $38.53 / +0.07 (+0.18%) 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago 10/08/20 GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5% 07/29/20 GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER GSK GlaxoSmithKline $38.53 / +0.07 (+0.18%) 01/12/21 GSK looks to double blockbusters in portfolio by 2026, Bloomberg says 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 12/11/20 GlaxoSmithKline offered $120 per share for Eidos Therapeutics, Bloomberg says GSK GlaxoSmithKline $38.53 / +0.07 (+0.18%) 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday 03/02/21 2021 London Global Healthcare Virtual Conference 02/03/21 GlaxoSmithKline - GSK GSK GlaxoSmithKline $38.53 / +0.07 (+0.18%) 09/04/20 GlaxoSmithKline call volume above normal and directionally bullish 08/03/20 Unusually active option classes on open August 3rd 07/31/20 Unusually active option classes on open July 31st
Hot Stocks	Weis Markets CFO Scott Frost to retire, Michael Lockard to succeed » 05:28 01/20/21 01/20 05:28 01/20/21 05:28 WMK Weis Markets $47.52 / -0.97 (-2.00%) Weis Markets announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial

Events

Earnings calls, analyst events, roadshows and more

Today at 07:00

MBA Mortgage Applications: Composite Index W/W: 1/15/2021 Government Event
Today at 07:00

MBA Mortgage Applications: Purchase Index W/W: 1/15/2021 Government Event
Today at 07:00

MBA Mortgage Applications: Refinance Index W/W: 1/15/2021 Government Event
CALT
Today at 07:00

Calliditas Therapeutics Firm Sponsored Meetings

Virtual Meeting
CFG
Today at 08:00

Citizens Financial - CFG Conference Calls
BK
Today at 08:00

BNY Mellon - BK Conference Calls
MESO
Today at 08:00

Mesoblast - MESO Conference Calls
Today at 08:00

Homebuilders Industry Meetings

Virtual Meeting
FNB
Today at 08:15

F.N.B. - FNB Conference Calls
MS
Today at 08:30

Morgan Stanley - MS Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	DSS X DSS Document Security Spot Secondary Managers: Aegis Priced at: $3.60 6.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	BDGE X BDGE Bridge Bancorp Block Trade Managers: Morgan Stanley $25.50-26.50 700K Shares TCRR X TCRR TCR2 Therapeutics Secondary Managers: Goldman Sachs, Jefferies, Piper Sandler & BMO Capital $32.80 Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRS X ACRS Aclaris Therapeutics Spot Secondary Managers: Cantor Fitzgerald & William Blair, H.C. Wainwright $17.00-18.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRX X ACRX AcelRx Spot Secondary Managers: Cantor Fitzgerald $1.90-2.00 BLRX X BLRX BioLineRx Spot Secondary Managers: H.C. Wainwright $3.17 4.167M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNGO X BNGO Bionano Genomics Spot Secondary Managers: Oppenheimer, BTIG, Ladenburg, Maxim $9.14 CYRX X CYRX Cryoport Spot Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS $64.18 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FULC X FULC Fulcrum Therapeutics Spot Secondary Managers: SVB Leerink, Piper Sandler & Credit Suisse $11.73 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LAC X LAC Lithium Americas Spot Secondary Managers: Canaccord, Deutsche Bank, Evercore ISI, Stifel $22.00-23.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PERI X PERI Perion Network Spot Secondary Managers: Oppenheimer, Stifel, Roth Capital, LAKE $13.96 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYRS X SYRS Syros Pharmaceuticals Spot Secondary Managers: Cowen & Piper Sandler $14.95 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	DFH X DFH Dream Finders Homes IPO Managers: BofA, RBC Capital & BTIG, Builder Advisor, Zelman, TCB Capital, Wedbush $12.00-15.00 9.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MYTE X MYTE Mytheresa IPO Managers: Morgan Stanley & JPMorgan, Credit Suisse, UBS, Jefferies, Cowen $24.00-26.00 15.647M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RLX X RLX RLX Technology IPO Managers: Citi, China Renaissance $8.00-10.00 116.5M Shares ATHA X ATHA Athira Pharma Secondary Managers: Goldman Sachs, Jefferies, Stifel & JMP Securities $26.55 4M Shares CDNA X CDNA CareDx Secondary Managers: Goldman Sachs & Jefferies, Raymond James, BTIG, Craig-Hallum, H.C. Wainwright $93.33 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CMRX X CMRX Chimerix Secondary Managers: Jefferies & Cowen, H.C. Wainwright, JonesTrading $8.10 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CTMX X CTMX CytomX Therapeutics Secondary Managers: JPMorgan, Cowen & Piper Sandler $8.48 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CYRX X CYRX Cryoport Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS $76.12 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DYN X DYN Dyne Therapeutics Secondary Managers: JPMorgan, Jefferies, Piper Sandler & Stifel $28.61 5.5M Shares EDIT X EDIT Editas Medicine Secondary Managers: JPMorgan & Morgan Stanley, Cowen, Credit Suisse $72.11 3.5M Shares MRUS X MRUS Merus Secondary Managers: Jefferies & SVB Leerink $24.71 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	PAX X PAX Patria IPO Managers: JPMorgan, BofA & Credit Suisse, Goldman Sachs, Bradesco BBI, BTG Pactual, ITAU, Keefe Bruyette, Santander, XP $14.00-16.00 26.65M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AZEK X AZEK Azek Secondary Managers: Barclays, BofA, Goldman Sachs & Jefferies $42.25 17.5M Shares CRSR X CRSR Corsair Gaming Secondary Managers: Goldman Sachs, Barclays, Credit Suisse, Macquarie, Baird, Cowen, & Stifel, Wedbush, Academy Securities $37.73 7.5M Shares PASG X PASG Passage Bio Secondary Managers: JPMorgan, Goldman Sachs & Cowen, Wedbush, Chardan $29.05 7M Shares
Fri	No deals

View All Syndicate Announcements »

Eli Lilly says updated purchase of LY-CoV555 to boost FY20 EPS view by 25c

TODAY'S FREE FLY STORIES

Get Full Fly Access